Business Description
Sumitomo Pharma Co Ltd
NAICS : 325412
ISIN : JP3495000006
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.3 | |||||
Equity-to-Asset | 0.14 | |||||
Debt-to-Equity | 3.41 | |||||
Debt-to-EBITDA | -1.76 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -0.7 | |||||
Beneish M-Score | -4.32 | |||||
WACC vs ROIC |
Growth Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -15.2 | |||||
3-Year Book Growth Rate | -35.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 4.73 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 86.66 | |||||
9-Day RSI | 70.37 | |||||
14-Day RSI | 67.93 | |||||
6-1 Month Momentum % | 79.17 | |||||
12-1 Month Momentum % | 44.78 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.64 | |||||
Quick Ratio | 0.42 | |||||
Cash Ratio | 0.24 | |||||
Days Inventory | 285.35 | |||||
Days Sales Outstanding | 89.33 | |||||
Days Payable | 154.34 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -30.74 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 59.56 | |||||
Operating Margin % | -80.7 | |||||
Net Margin % | -81.55 | |||||
FCF Margin % | -22.59 | |||||
ROE % | -108.97 | |||||
ROA % | -28.54 | |||||
ROIC % | -23.99 | |||||
3-Year ROIIC % | -807.39 | |||||
ROC (Joel Greenblatt) % | -383.21 | |||||
ROCE % | -47.99 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 0.68 | |||||
PB Ratio | 2.04 | |||||
EV-to-EBIT | -1.99 | |||||
EV-to-Forward-EBIT | -8.05 | |||||
EV-to-EBITDA | -2.28 | |||||
EV-to-Forward-EBITDA | 16.99 | |||||
EV-to-Revenue | 1.48 | |||||
EV-to-Forward-Revenue | 1.27 | |||||
EV-to-FCF | -6.46 | |||||
Price-to-Projected-FCF | 7.41 | |||||
Price-to-Median-PS-Value | 0.49 | |||||
Earnings Yield (Greenblatt) % | -50.25 | |||||
FCF Yield % | -33.62 | |||||
Forward Rate of Return (Yacktman) % | 17.41 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:DNPUF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Sumitomo Pharma Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 2,307.533 | ||
EPS (TTM) ($) | -4.782 | ||
Beta | 0.23 | ||
Volatility % | 80.63 | ||
14-Day RSI | 67.93 | ||
14-Day ATR ($) | 0.007534 | ||
20-Day SMA ($) | 4.3 | ||
12-1 Month Momentum % | 44.78 | ||
52-Week Range ($) | 1.99 - 4.5 | ||
Shares Outstanding (Mil) | 397.29 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Sumitomo Pharma Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Sumitomo Pharma Co Ltd Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Sumitomo Pharma Co Ltd Frequently Asked Questions
What is Sumitomo Pharma Co Ltd(DNPUF)'s stock price today?
When is next earnings date of Sumitomo Pharma Co Ltd(DNPUF)?
Does Sumitomo Pharma Co Ltd(DNPUF) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |